AbbVie announced that RINVOQ (upadacitinib) demonstrated sustained facial and total body repigmentation in non-segmental vitiligo patients through 76 weeks in Phase 3 Viti-Up-1 and Viti-Up-2 studies. The data, presented at the 2026 EADV Congress, also showed that combining RINVOQ with narrowband UVB phototherapy led to higher repigmentation rates compared to RINVOQ alone. These findings support RINVOQ as the first systemic treatment approved in the EU for vitiligo and suggest further research into combination therapies. Safety results were consistent with known profiles, with no new concerns reported.
AbbVie's presentation of promising long-term data for RINVOQ in vitiligo treatment comes as its shares trade near their yearly peak. On Pluang, ABBV is priced at USD 261.15, slightly down by 0.24% as of Oct 01, 2026 21:15 WIB, with a market cap of $462.26 billion. Investor interest remains strong, reflected in a 77% buy order activity and a dividend yield of 2.65%.
Five dividend-paying stocks from consumer staples, financials, real estate, and healthcare sectors—Coca-Cola, PepsiCo, JPMorgan Chase, Realty Income, and AbbVie—are highlighted for their strong cash flow and consistent dividend growth. Each company c...
AbbVie will announce its third-quarter 2026 financial results on October 30, 2026, before the market opens. The company will host a live webcast of the earnings call at 8 a.m. Central time, accessible via its Investor Relations website. This event is...
Bank of America increased price targets for AbbVie to $289 and Johnson & Johnson to $278, maintaining Buy and Neutral ratings respectively. AbbVie is favored due to its strong growth potential, robust pipeline, and attractive valuation at 16 times fo...
AbbVie announced positive Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment, showing meaningful weight loss of up to 9.8% over 12-13 weeks with weekly, biweekly, and monthly dosing options. The drug demonstrated a half-l...
AbbVie announced positive Phase 2 results for zumilokibart, a monoclonal antibody targeting IL-13, in adults with moderate-to-severe atopic dermatitis. All dose regimens met the primary endpoint with significant improvements in skin severity and itch...
